INTRODUCTION: A Case Control Etiology of Sarcoidosis Study (ACCESS) sarcoidosis organ assessment instrument has been used for more than a decade to establish uniform standards for the probability of sarcoidosis organ involvement. The ACCESS instrument has become increasingly outdated as new technologies have been developed. Furthermore, the ACCESS instrument failed to address all possible organs involved with sarcoidosis. For these reasons, the World Association of Sarcoidosis and Other Granulomatous Diseases (WASOG) developed a new sarcoidosis organ assessment instrument. METHODS: Clinical sarcoidosis experts assessed various clinical manifestations for the probability of sarcoidosis organ involvement. Two criteria were required to apply this assessment: 1) histologic evidence of granulomatous inflammation of unknown cause in an organ that was not being assessed; 2) the clinical manifestation being addressed required that alternative causes other than sarcoidosis had been reasonably excluded. Clinical manifestations were assessed as either: a) highly probable: likelihood of sarcoidosis causing this manifestation of at least 90%.; b) probable: likelihood of sarcoidosis causing this manifestation of between 50 and 90%; c) possible: likelihood of sarcoidosis causing this manifestation of less than 50%. The sarcoidosis experts voted on the likelihood of sarcoidosis causing each manifestation using Delphi study methodology where at least 70% agreement of the experts was needed for consensus. RESULTS: Various clinical manifestations were classified as highly probable, at least probable, possible, or indeterminate when no consensus could be reached. CONCLUSION: An instrument was developed by expert opinion that may be useful for the clinician and researcher in establishing criteria for sarcoidosis organ involvement.
INTRODUCTION: A Case Control Etiology of Sarcoidosis Study (ACCESS) sarcoidosis organ assessment instrument has been used for more than a decade to establish uniform standards for the probability of sarcoidosis organ involvement. The ACCESS instrument has become increasingly outdated as new technologies have been developed. Furthermore, the ACCESS instrument failed to address all possible organs involved with sarcoidosis. For these reasons, the World Association of Sarcoidosis and Other Granulomatous Diseases (WASOG) developed a new sarcoidosis organ assessment instrument. METHODS: Clinical sarcoidosis experts assessed various clinical manifestations for the probability of sarcoidosis organ involvement. Two criteria were required to apply this assessment: 1) histologic evidence of granulomatous inflammation of unknown cause in an organ that was not being assessed; 2) the clinical manifestation being addressed required that alternative causes other than sarcoidosis had been reasonably excluded. Clinical manifestations were assessed as either: a) highly probable: likelihood of sarcoidosis causing this manifestation of at least 90%.; b) probable: likelihood of sarcoidosis causing this manifestation of between 50 and 90%; c) possible: likelihood of sarcoidosis causing this manifestation of less than 50%. The sarcoidosis experts voted on the likelihood of sarcoidosis causing each manifestation using Delphi study methodology where at least 70% agreement of the experts was needed for consensus. RESULTS: Various clinical manifestations were classified as highly probable, at least probable, possible, or indeterminate when no consensus could be reached. CONCLUSION: An instrument was developed by expert opinion that may be useful for the clinician and researcher in establishing criteria for sarcoidosis organ involvement.
Authors: Sanjay Divakaran; Garrick C Stewart; Neal K Lakdawala; Robert F Padera; Wunan Zhou; Akshay S Desai; Michael M Givertz; Mandeep R Mehra; Raymond Y Kwong; Sandeep S Hedgire; Brian B Ghoshhajra; Viviany R Taqueti; Hicham Skali; Sharmila Dorbala; Ron Blankstein; Marcelo F Di Carli Journal: Circ Cardiovasc Imaging Date: 2019-06-10 Impact factor: 7.792
Authors: Marc A Judson; Amit Chopra; Edward Conuel; Efstratios Koutroumpakis; Christopher Schafer; Adam Austin; Robert Zhang; Kerry Cao; Rani Berry; Malik M H S Khan; Aakash Modi; Ritu Modi; Stephanie Jou; Furqan Ilyas; Recai M Yucel Journal: Lung Date: 2017-07-13 Impact factor: 2.584
Authors: Panithaya Chareonthaitawee; Rob S Beanlands; Wengen Chen; Sharmila Dorbala; Edward J Miller; Venkatesh L Murthy; David H Birnie; Edward S Chen; Leslie T Cooper; Roderick H Tung; Eric S White; Salvador Borges-Neto; Marcelo F Di Carli; Robert J Gropler; Terrence D Ruddy; Thomas H Schindler; Ron Blankstein Journal: J Nucl Cardiol Date: 2017-10 Impact factor: 5.952
Authors: Elliott D Crouser; Nabeel Y Hamzeh; Lisa A Maier; Mark W Julian; May Gillespie; Mohammad Rahman; David Baxter; Xiaogang Wu; S Patrick Nana-Sinkam; Kai Wang Journal: Am J Respir Crit Care Med Date: 2017-10-01 Impact factor: 21.405
Authors: Panithaya Chareonthaitawee; Rob S Beanlands; Wengen Chen; Sharmila Dorbala; Edward J Miller; Venkatesh L Murthy; David H Birnie; Edward S Chen; Leslie T Cooper; Roderick H Tung; Eric S White; Salvador Borges-Neto; Marcelo F Di Carli; Robert J Gropler; Terrence D Ruddy; Thomas H Schindler; Ron Blankstein Journal: J Nucl Med Date: 2017-08 Impact factor: 10.057